<html>
 <body>
  <div class="col-md-12" id="content" style="">
   <div class="hidden" data-drupal-messages-fallback="">
   </div>
   <div class="widget block" id="block-medsites-page-title">
    <h1>
     <span property="schema:name">
      Hepatorenal Syndrome
     </span>
    </h1>
   </div>
   <div class="widget block" id="block-medsites-content">
    <article about="/commodorecompendium/hepatorenal-syndrome" data-history-node-id="945" role="article" typeof="schema:WebPage">
     <div>
      <div class="field field--name-body field--type-text-with-summary field--label-hidden field__item" property="schema:text">
       <div class="WordSection1">
        <table class="TableGrid8" style="width:100.0%; border-collapse:collapse; border:none" width="100%">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>AKI &amp; Hepatorenal Syndrome (HRS) – Garren Montgomery</td>
    </tr>
  </tbody>
</table>
        </table>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Background
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Circulatory dysfunction: Portal HTN causes shear stress on portal vessels; endothelium releases vasodilators (NO, prostanoids). This causes splanchnic vasodilation and reduced effective blood volume (decreased MAP) which activates RAAS and the sympathetic nervous system. This results in avid sodium and water retention and severe renal vasoconstriction.
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Inflammation: Bacterial translocation (as seen in SBP) results in increased circulating pro-inflammatory cytokines which can worsen splanchnic vasodilation and also thought to act directly on proximal tubular cells to cause further intrarenal RAAS activation and
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style='font-family:"Times New Roman",serif'>
                ↓
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                GFR
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Definitions:
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <b>
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   HRS-AKI
                  </span>
                 </span>
                </b>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  (formerly type I HRS): Absolute
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style='font-family:"Wingdings 3"'>
                  #
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  in Cr ≥0.3 mg/dl within 48h OR Percent
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style='font-family:"Wingdings 3"'>
                  #
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  in Cr ≥50% using last available value of outpatient Cr within 3 months as baseline
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
            <ul>
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <b>
                   <span style="font-size:12.0pt">
                    <span style="font-family:Palatino">
                     HRS-NAKI
                    </span>
                   </span>
                  </b>
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    (“non-AKI”): (formerly type II HRS):
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="vertical-align:baseline">
                  <span style="font-family:Calibri,sans-serif">
                   <b>
                    <span style="font-size:12.0pt">
                     <span style="font-family:Palatino">
                      HRS-AKD
                     </span>
                    </span>
                   </b>
                   <span style="font-size:12.0pt">
                    <span style="font-family:Palatino">
                     : eGFR<60 for
                     <b>
                      <
                     </b>
                     3 months in absence of other structural causes OR Percent
                    </span>
                   </span>
                   <span style="font-size:12.0pt">
                    <span style='font-family:"Wingdings 3"'>
                     #
                    </span>
                   </span>
                   <span style="font-size:12.0pt">
                    <span style="font-family:Palatino">
                     in Cr ≤50% using last available Cr over last 3 months as baseline
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="vertical-align:baseline">
                  <span style="font-family:Calibri,sans-serif">
                   <b>
                    <span style="font-size:12.0pt">
                     <span style="font-family:Palatino">
                      HRS-CKD
                     </span>
                    </span>
                   </b>
                   <span style="font-size:12.0pt">
                    <span style="font-family:Palatino">
                     : eGFR<60 for
                     <b>
                      ≥
                     </b>
                     3 months in absence of other
                    </span>
                   </span>
                   <span style="font-size:12.0pt">
                    <span style='font-family:"Times New Roman",serif'>
                     structural causes
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
            </ul>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Diagnostic Criteria
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Presence of cirrhosis with ascites
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Diagnosis of AKI (see above)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  No response or inadequate response at 48 hrs after volume expansion w/ albumin and withdrawal of diuretics
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Absence of shock
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  No current or recent use of nephrotoxic drugs
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Absence of proteinuria (<500 mg/d), absence of hematuria (<50 RBCs per HPF), normal renal ultrasound (this criterion would not be included if patient has known CKD such as diabetic or hypertensive nephropathy)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Suggestion of renal vasoconstriction with FeNa <0.2, FeUrea <20 (most sensitive diagnostic measure). UNa <20 is suggestive but not diagnostic given baseline sodium avidity in cirrhosis and inability to calculate FeNa
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Cut off for ATN in cirrhosis is a FeNa >0.5, rather than 1 in the general population
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Evaluation
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Step 1: Exclude other obvious causes of renal injury
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
          <ul>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  DDx: Pre-renal (most common), ATN (2
                  <sup>
                   nd
                  </sup>
                  most common), AIN, bile cast nephropathy, IgA nephropathy, cryoglobulinemia/MPGN (HCV), membranous nephropathy (HBV), post renal (rare)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Common precipitants of AKI: infection, overdiuresis, GI bleeding, recent LVP without subsequent volume expansion, nephrotoxic drugs/NSAIDs
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Workup: BMP, UA w/ microscopy, Urine electrolytes (FeNa, FeUrea), urine protein/Cr ratio, renal ultrasound (to assess for chronicity)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Step 2: Diuretic cessation/albumin challenge
               </span>
              </span>
             </b>
            </span>
           </span>
          </span>
          <ul>
           <li>
            <span style="font-size:11pt">
             <span style="line-height:normal">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 STOP all diuretics, beta blockers, NSAIDs, ACE/ARBs, anti-hypertensives, vasodilators, nephrotoxins
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="font-size:11pt">
             <span style="line-height:normal">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 START volume expansion with albumin 1g/kg/day (up to a max of 100 g/day) for 2 consecutive days
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="font-size:11pt">
             <span style="line-height:normal">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Infection is a common precipitant of HRS, assess for ascites and perform diagnostic para to r/o SBP
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Step
               </span>
              </span>
             </b>
             <b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                3: Diagnosis of HRS
               </span>
              </span>
             </b>
            </span>
           </span>
          </span>
          <ul>
           <li>
            <span style="font-size:11pt">
             <span style="line-height:normal">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 If no other clear cause of AKI is identified and SCr has not improved after 48 hours of diuretic cessation and volume expansion proceed promptly to treatment. If suspicion for HRS is high, therapy can be started before the 48h mark
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
       </div>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             Management
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Pharmacologic therapies: (in order of preference):
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Terlipressin + albumin. Most effective combo based on clinical trials but not yet available in the U.S.
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Norepinephrine (NE, levophed) + albumin (25-50 g/day).
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Most likely to be used at VUMC, requires central access (PICC vs triple lumen) but can be administered on stepdown unit/8MCE.
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Guidelines recommend NE to be dosed at 0.5-3 mg/hr. Would ask fellow, attending or pharmacist for baseline. VUMC protocol for ICU and stepdown:
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="vertical-align:baseline">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Start NE gtt at 3mcg/min. If UOP is <200 or MAP <10mm Hg from baseline, increase gtt by 3mcg increments until those goals are met or max 20 mcg/min
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="vertical-align:baseline">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Albumin will continue to be infused at 50gm per day until replete and then stopped or modified depending on decision on rounds.
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="vertical-align:baseline">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   The use of furosemide to supplement volume removal will be made on a clinical basis on rounds by the attending and resident on service.
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
           </ul>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Continue to hold diuretics. LVP is still generally considered safe even in HRS if indicated by tense ascites. This can be attending specific and would confirm prior to performing.
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Therapy is generally continued until HRS is reversed or the hepatology attending deems it refractory to medical treatment
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Complete response to therapy defined as return of SCr within 0.3 mg/dL of baseline
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Patients with HRS-NAKI (formerly type II HRS) may respond to the above therapies, but recurrence of renal dysfunction after withdrawal of vasoconstrictors is the norm and thus current guidelines do not recommend them for this scenario
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              TIPS: Generally contraindicated for most HRS pts given high MELD scores and not much data to support its use, but may improve renal function in patients with HRS-NAKI with refractory ascites
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              RRT: Dialysis can be considered for those who fail to respond to pharmacologic therapy, particularly as a bridge to liver transplant. Decision to initiate should be individualized
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Liver transplant: The best and most definitive treatment regardless of response to pharmacologic therapy
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             Prevention of HRS:
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Ensure that pts receive albumin after LVP and when diagnosed with SBP. Ensure pts with cirrhosis with suspected UGIB receive ppx abx
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Avoid NSAIDs. Stop ACE/ARBs if possible. Stop beta blockers in patients with refractory ascites and AKI, hyponatremia or hypotension.
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
      </div>
     </div>
    </article>
   </div>
  </div>
 </body>
</html>